The investigators sequenced whole exomes from 76 HIV-negative individuals drawn from the Mizo population of Northeast India. Sequencing was performed on an Illumina NovaSeq 6000 platform with a reported mean coverage of 100X. Variant calling used GATK HaplotypeCaller v4.3 against GRCh38p14; ANNOVAR provided annotation. The study team applied hard-quality thresholds (QD ≥ 2, SOR ≤ 3, MQ ≥ 40, DP ≥ 10, GQ ≥ 20) to filter calls. These concrete steps produced the dataset analysed and form the technical backbone of subsequent frequency and enrichment comparisons versus gnomAD v2.1.1.
After quality filtering, the cohort dataset contained 12,011 sample-variants distributed across 2,821 unique genomic positions. Those positions mapped to 36 HIV-associated loci: 33 protein-coding genes, two chemokine ligands and three lncRNA targets. The authors reported these counts as the primary catalog of host variation in the sampled population. This catalogue provides both common and rare alleles for downstream interpretation in HIV susceptibility and pharmacogenomics research.
Within the filtered dataset, 784 observations—representing 51 unique positions—were classified as high-impact nonsynonymous or loss-of-function variants. The study team flagged these variants as more likely to affect gene function. The report did not include functional assays or clinical phenotype correlations; the authors limited their claims to variant annotation and predicted impact, using available in silico metrics (for example, CADD for at least one variant reported).
Investigators identified ADAR rs2229857 (p.K384R, NM_015840) as the single most frequently observed variant in this sample, with a reported Mizo carrier frequency of 0.895 (95% CI: 0.806–0.946). A different signal emerged for CXCR1 rs16858808 (p.R335C): the Mizo carrier frequency was 0.197 (95% CI: 0.123–0.300), and the authors reported a 7.65-fold carrier-frequency enrichment versus gnomAD South Asian. The report lists a CADD score of 15.60 for this CXCR1 variant, which the team used as part of its functional-priority rationale. These specific variants therefore anchor the study’s claim about population-enriched functional alleles.
Hardy-Weinberg equilibrium was assessed using the Wigginton exact test with Bonferroni correction. Sixteen of 20 tested variants deviated from equilibrium at the corrected threshold (p < 0.0025). The majority of deviations showed excess homozygosity. The authors interpreted this pattern as consistent with longstanding endogamy in the Mizo population, and they reported this as a pervasive genomic signature that shapes allele distributions in the cohort.
The authors specifically examined the well-known protective deletion CCR5-Δ32 and found it absent in all 76 individuals tested. They reported this null observation without extrapolating to regional prevalence beyond the sampled participants. The absence of CCR5-Δ32 is presented as a negative result that contrasts with some other global populations where that deletion occurs at measurable frequency.
The paper reports an exome-level catalogue and population-frequency comparisons but did not report functional validation experiments linking variants to HIV susceptibility or treatment response; investigators limited conclusions to genomic description. The cohort size and a single-population sampling frame constrain generalisability beyond the analysed group—those design limitations were documented in the abstract. The authors proposed the variant dataset as a population-specific foundation for future studies but did not provide timelines, clinical correlates, or downstream experimental plans in the abstract. Remaining clinical questions include whether the identified enriched variants (for example, CXCR1 rs16858808 or ADAR rs2229857) modulate infection risk, disease progression, or antiretroviral pharmacodynamics in Mizos, and whether the endogamy signal affects association study design. Those unanswered items map directly onto the next steps reported as necessary by the study team.